Sandoz.com


Main options

  • Return to Homepage
  • Follow this link to skip the site navigation and go straight to the beginning of the content
  • Follow this link to skip to the site navigation
  • Follow this link to find out more about this site
  • Follow this link to find accessibility information and assistance with accessing this site for impaired users

Quicklinks

  • Home
  • Media Room
    • Press Releases & News
    • Press Kit
    • Corporate Publications
    • Videos
    • Photo Archive
    • Media Contact
  • Contact
    • Overview
    • Contact Form
  • Sitemap

Main navigation

  • About Sandoz
    • Introduction
    • What we stand for
    • Management
    • Company Overview
    • Sandoz Worldwide
  • Quality Generics
    • Introduction
    • Quality Standards
    • Development
    • FAQ
  • Product Range
    • Introduction
    • Therapeutic Areas
    • Difficult-to-Make
    • More about Biosimilars
      • Biosimilar Presentation
    • Anti-Infectives
    • Biopharm Cooperations
      • About
      • Recombinant Microbial
      • Quality
      • Services
      • Fill and Finish
      • Contact Us
  • Social Responsibility
    • Introduction
    • Community Partnership Day
    • Tuberculosis
    • Sandoz International TB symposium
    • Peru Hospital
    • Local & Community Initiatives
  • Global Career
    • Introduction
    • Job Offers

Change fontsize:

  • Decrease fontsize
  • Reset fontsize
  • Increase fontsize

Currently selected main menu item

Follow this link to skip to the main content
  • Press Releases & News
  • Press Kit
  • Corporate Publications
  • Videos
  • Photo Archive
  • Media Contact
 

  • Home
  • Media Room
  • Press Releases & News

Global News

«12»
  • 18-10-2007Latest Results - Q3 2007

    Novartis delivers record earnings in first nine months of 2007 thanks to strong operational performance and divestment gains

  • 31-08-2007European Commission Approval for biosimilar epoetin alfa

    The European Commission's decision to grant this approval followed a positive opinion in June from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP), which reviews medicines scientifically for the Commission.

  • 03-08-2007Sandoz launches generic version of Toprol XL® 50 mg ER tablet

    Princeton, New Jersey; August 2, 2007 -- Sandoz introduced metoprolol succinate 50 mg extended release tablets, a generic equivalent of Toprol XL®, in the U.S. today.

  • 17-07-2007Latest Results - Halfyear 2007

    Novartis delivers strong performance in first half of 2007 (H1 - Report)

  • 22-06-2007Positive EU opinion

    Sandoz receives positive EU opinion for approval of epoetin alfa biosimilar

  • 24-04-2007Latest Results - Q1 2007

    Novartis with dynamic growth in the 2007 first quarter(Q1-Media release)

  • 18-01-2007Latest Results - Q1 2007

    Novartis strategic healthcare portfolio drives sustained strong performance with record full-year results in 2006

  • print this page

Sandoz Websites

  • Sandoz Algeria
  • Sandoz Austria
  • Sandoz Bangladesh
  • Sandoz Belgium
  • Sandoz Canada
  • Sandoz China
  • Sandoz Czech Republic
  • Sandoz Danmark
  • Sandoz England
  • Sandoz Finland
  • Sandoz France
  • Sandoz Germany
  • Sandoz Hungary
  • Sandoz Italy
  • Sandoz Japan
  • Sandoz Latvia
  • Sandoz Lithuania
  • Sandoz Netherlands
  • Sandoz Norway
  • Sandoz Slovakia
  • Sandoz South Africa
  • Sandoz Spain
  • Sandoz Sweden
  • Sandoz Switzerland
  • Sandoz Turkey
  • Sandoz United States

Sandoz Theme map

Sandoz Theme map

See what are the current hot topics at Sandoz

  • Explore

Frequently asked questions

Frequently asked questions

Everything you wanted to know about the generics industry

  • More

Find out more about this site

  • Imprint
  • Disclaimer
  • Privacy Policy
  • © Sandoz 2007
Sandoz is a Novartis company